Premature menopause and risk of neurological disease: Basic mechanisms and clinical implications

Molecular and Cellular Endocrinology

Volumn 389, Issue 1-2, 2014, Pages 2-6

  Scott, Erin L ^a   Zhang, Quan guang ^a   Vadlamudi, Ratna K ^b   Brann, Darrell W ^a  

^a AUGUSTA UNIVERSITY   (United States)

^b University of Texas Health Science Center   (United States)

Author keywords

Dementia; Estradiol; Estrogen; Menopause; Neurological disease

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ESTROGEN;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; CANCER RISK; DEMENTIA; EARLY MENOPAUSE; ESTROGEN THERAPY; HIPPOCAMPAL CA1 REGION; HUMAN; HYSTERECTOMY; MORTALITY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OVARIECTOMY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VENOUS THROMBOEMBOLISM; COHORT ANALYSIS; FEMALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK; WOMEN'S HEALTH;

COHORT STUDIES; ESTROGENS; FEMALE; HUMANS; MENOPAUSE, PREMATURE; NERVOUS SYSTEM DISEASES; RISK; WOMEN'S HEALTH;

EID: 84901508704     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.01.013     Document Type: Review

References (56)

1. Acosta J.I., Hiroi R., Camp B.W., Talboom J.S., Bimonte-Nelson H.A. An update on the cognitive impact of clinically-used hormone therapies in the female rat: models, mazes, and mechanisms. Brain Res. 2013, 1514:18-39.
2. Armstrong K., Schwartz J.S., Randall T., Rubin S.C., Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2004, 22:1045-1054.
3. Bove R., Secor E., Chibnik L.B., Barnes L.L., Schneider J.A., Bennett D.A., De Jager P.L. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2013.
4. Brann D.W., Dhandapani K., Wakade C., Mahesh V.B., Khan M.M. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007, 72:381-405.
5. Brinton R.D. Requirements of a brain selective estrogen: advances and remaining challenges for developing a NeuroSERM. J. Alzheimer's Dis.: JAD 2004, 6:S27-S35.
6. Brinton R.D. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann. N. Y. Acad. Sci. 2005, 1052:57-74.
7. Brinton R.D. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci. 2008, 31:529-537.
8. Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Levesque H., Trillot N., Barrellier M.T., Wahl D., Emmerich J., Scarabin P.Y., Estrogen, Thromboembolism Risk Study G Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007, 115:840-845.
9. Canonico M., Fournier A., Carcaillon L., Olie V., Plu-Bureau G., Oger E., Mesrine S., Boutron-Ruault M.C., Clavel-Chapelon F., Scarabin P.Y. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 2010, 30:340-345.
10. de Villiers T.J., Gass M.L., Haines C.J., Hall J.E., Lobo R.A., Pierroz D.D., Rees M. Global Consensus Statement on menopausal hormone therapy. Maturitas 2013, 74:391-392.
11. Ding F., Yao J., Zhao L., Mao Z., Chen S., Brinton R.D. Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's. PLoS ONE 2013, 8:e59825.
12. Duan L., Xu X., Koebnick C., Lacey J.V., Sullivan-Halley J., Templeman C., Marshall S.F., Neuhausen S.L., Ursin G., Bernstein L., Henderson K.D. Bilateral oophorectomy is not associated with increased mortality: the California Teachers Study. Fertil. Steril. 2012, 97:111-117.
13. Hamilton R.T., Rettberg J.R., Mao Z., To J., Zhao L., Appt S.E., Register T.C., Kaplan J.R., Brinton R.D. Hippocampal responsiveness to 17beta-estradiol and equol after long-term ovariectomy: implication for a therapeutic window of opportunity. Brain Res. 2011, 1379:11-22.
14. Harman S.M., Brinton E.A., Cedars M., Lobo R., Manson J.E., Merriam G.R., Miller V.M., Naftolin F., Santoro N. KEEPS: the Kronos early estrogen prevention study. Climacteric: J. Int. Menopause Soc. 2005, 8:3-12.
15. Henderson V.W., Brinton R.D. Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy. Prog. Brain Res. 2010, 182:77-96.
16. Jacoby V.L., Grady D., Wactawski-Wende J., Manson J.E., Allison M.A., Kuppermann M., Sarto G.E., Robbins J., Phillips L., Martin L.W., O'Sullivan M.J., Jackson R., Rodabough R.J., Stefanick M.L. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch. Intern. Med. 2011, 171:760-768.
17. Jin M., Yu Y., Huang H. An update on primary ovarian insufficiency. Sci. China Life Sci. 2012, 55:677-686.
18. Kato I., Toniolo P., Akhmedkhanov A., Koenig K.L., Shore R., Zeleniuch-Jacquotte A. Prospective study of factors influencing the onset of natural menopause. J. Clin. Epidemiol. 1998, 51:1271-1276.
19. LaCroix A.Z., Chlebowski R.T., Manson J.E., Aragaki A.K., Johnson K.C., Martin L., Margolis K.L., Stefanick M.L., Brzyski R., Curb J.D., Howard B.V., Lewis C.E., Wactawski-Wende J., Investigators WHI Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA: J. Am. Med. Assoc. 2011, 305:1305-1314.
20. Maki P.M. Hormone therapy and cognitive function: is there a critical period for benefit?. Neuroscience 2006, 138:1027-1030.
21. Menon D.V., Vongpatanasin W. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treatments Endocrinol. 2006, 5:37-51.
22. Miller V.M., Black D.M., Brinton E.A., Budoff M.J., Cedars M.I., Hodis H.N., Lobo R.A., Manson J.E., Merriam G.R., Naftolin F., Santoro N., Taylor H.S., Harman S.M. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J. Cardiovasc. Translational Res. 2009, 2:228-239.
23. Morrison J.H., Brinton R.D., Schmidt P.J., Gore A.C. Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J. Neurosci.: Official J. Soc. Neurosci. 2006, 26:10332-10348.
24. Nahas E., Pontes A., Traiman P., NahasNeto J., Dalben I., De Luca L. Inhibin B and ovarian function after total abdominal hysterectomy in women of reproductive age. Gynecol. Endocrinol.: Official J. Int. Soc. Gynecol. Endocrinol. 2003, 17:125-131.
25. Parker W.H. Bilateral oophorectomy versus ovarian conservation: effects on long-term women's health. J. Minim. Invasive Gynecol. 2010, 17:161-166.
26. Parker W.H. Ovarian conservation versus bilateral oophorectomy at the time of hysterectomy for benign disease. Menopause 2013, (Epub ahead of print).
27. Parker W.H., Broder M.S., Chang E., Feskanich D., Farquhar C., Liu Z., Shoupe D., Berek J.S., Hankinson S., Manson J.E. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet. Gynecol. 2009, 113:1027-1037.
28. Parker W.H., Feskanich D., Broder M.S., Chang E., Shoupe D., Farquhar C.M., Berek J.S., Manson J.E. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet. Gynecol. 2013, 121:709-716.
29. Phung T.K., Waltoft B.L., Laursen T.M., Settnes A., Kessing L.V., Mortensen P.B., Waldemar G. Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement. Geriatr. Cogn. Disord. 2010, 30:43-50.
30. Raz L., Zhang Q.G., Han D., Dong Y., De Sevilla L., Brann D.W. Acetylation of the pro-apoptotic factor, p53 in the hippocampus following cerebral ischemia and modulation by estrogen. PLoS ONE 2011, 6:e27039.
31. Rettberg J.R., Yao J., Brinton R.D. Estrogen: a master regulator of bioenergetic systems in the brain and body. Frontiers Neuroendocrinol. 2013, (Epub ahead of print).
32. Rivera C.M., Grossardt B.R., Rhodes D.J., Rocca W.A. Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology 2009, 33:32-40.
33. Rocca W.A., Ulrich L.G. Oophorectomy for whom and at what age? Primum non nocere. Maturitas 2012, 71:1-2.
34. Rocca W.A., Grossardt B.R., de Andrade M., Malkasian G.D., Melton L.J. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006, 7:821-828.
35. Rocca W.A., Bower J.H., Maraganore D.M., Ahlskog J.E., Grossardt B.R., de Andrade M., Melton L.J. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007, 69:1074-1083.
36. Rocca W.A., Shuster L.T., Grossardt B.R., Maraganore D.M., Gostout B.S., Geda Y.E., Melton L.J. Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Women's Health 2009, 5:39-48.
37. Rocca W.A., Grossardt B.R., Shuster L.T. Oophorectomy, menopause, estrogen, and cognitive aging: the timing hypothesis. Neuro-Degenerative Dis. 2010, 7:163-166.
38. Rocca W.A., Grossardt B.R., Shuster L.T. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res. 2011, 1379:188-198.
39. Rocca W.A., Grossardt B.R., Miller V.M., Shuster L.T., Brown R.D. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012, 19:272-277.
40. Rocca W.A., Grossardt B.R., Shuster L.T., Stewart E.A. Hysterectomy, oophorectomy, estrogen, and the risk of dementia. Neuro-Degenerative Dis. 2012, 10:175-178.
41. Sarrel P.M., Njike V.Y., Vinante V., Katz D.L. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am. J. Public Health 2013, 103:1583-1588.
42. Scott E., Zhang Q.G., Wang R., Vadlamudi R., Brann D. Estrogen neuroprotection and the critical period hypothesis. Front. Neuroendocrinol. 2012, 33:85-104.
43. Scott E.L., Zhang Q.G., Han D., Desai B.N., Brann D.W. Long-term estrogen deprivation leads to elevation of Dickkopf-1 and dysregulation of Wnt/beta-Catenin signaling in hippocampal CA1 neurons. Steroids 2013, 78:624-632.
44. Sherwin B.B. The critical period hypothesis: can it explain discrepancies in the oestrogen-cognition literature?. J. Neuroendocrinol. 2007, 19:77-81.
45. Shuster L.T., Gostout B.S., Grossardt B.R., Rocca W.A. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 2008, 14:111-116.
46. Shuster L.T., Rhodes D.J., Gostout B.S., Grossardt B.R., Rocca W.A. Premature menopause or early menopause: long-term health consequences. Maturitas 2010, 65:161-166.
47. Siddle N., Sarrel P., Whitehead M. The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil. Steril. 1987, 47:94-100.
48. Simpkins J.W., Perez E., Wang X., Yang S., Wen Y., Singh M. The potential for estrogens in preventing Alzheimer's disease and vascular dementia. Therap. Adv. Neurol. Disorders 2009, 2:31-49.
49. Singh M., Su C. Progesterone and neuroprotection. Horm. Behav. 2013, 63:284-290.
50. Singh M., Su C. Progesterone-induced neuroprotection: Factors that may predict therapeutic efficacy. Brain Res. 2013, 1514:98-106.
51. Xiangying H., Lili H., Yifu S. The effect of hysterectomy on ovarian blood supply and endocrine function. Climacteric: J. Int. Menopause Soc. 2006, 9:283-289.
52. Yao J., Brinton R.D. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv. Pharmacol. 2012, 64:327-371.
53. Yao J., Hamilton R.T., Cadenas E., Brinton R.D. Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochim. Biophys. Acta 2010, 1800:1121-1126.
54. Yao J., Irwin R., Chen S., Hamilton R., Cadenas E., Brinton R.D. Ovarian hormone loss induces bioenergetic deficits and mitochondrial beta-amyloid. Neurobiol. Aging 2012, 33:1507-1521.
55. Zhang Q.G., Han D., Wang R.M., Dong Y., Yang F., Vadlamudi R.K., Brann D.W. C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection. Proc. Nat. Acad. Sci. USA 2011, 108:E617-E624.
56. Zhang Q.G., Wang R.M., Scott E., Han D., Dong Y., Tu J.Y., Yang F., Reddy Sareddy G., Vadlamudi R.K., Brann D.W. Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause. Brain: J. Neurol. 2013, 136:1432-1445.